Abstract
INTRODUCTION
Severe pulmonary hypertension (PH) is a risk factor for impaired outcomes following lung transplantation. A very severe form of PH is idiopathic pulmonary artery hypertension (IPAH), which is characterized by vascular proliferation and remodelling of the small pulmonary arteries, leading to a progressive increase in pulmonary vascular resistance and eventual death due to the right ventricular failure [1, 2] .
Combined heart-lung transplantation or bilateral lung transplantation are established therapies for IPAH [3] [4] [5] . However, cardiopulmonary support during bilateral lung transplantation is always mandatory due to risk of right heart failure after selective clamping of 1 pulmonary artery. Moreover, in this cohort of patients, the development of primary graft dysfunction (PGD) is common complication early postoperatively [6, 7] .
Recently, extracorporeal membrane oxygenation (ECMO) has been successfully used for pre-, intra-and postoperative cardiopulmonary support in patients undergoing lung transplantation, especially for severe PH [8] [9] [10] . Since May 2010, all patients at our institution with severe PH have been transplanted on venoarterial ECMO support, which has been extended postoperatively for a minimum of 5 days in order to avoid PGD and allow for early extubation and improvement in left ventricular volume uptake [11] .
The aim of this study was to investigate the changes in left and right ventricular dimensions and function after 1 year in patients with severe PH transplanted using our prophylactic ECMO protocol, and to compare outcomes and survival of these patients with our contemporary cohort of lung transplant patients with underlying diseases other than severe PH.
MATERIALS AND METHODS

Patients
A retrospective study was performed in a single university centre. All patients who underwent lung transplantation between May 2010 and January 2016 at our institution were included in the study. For the purpose of this analysis, patients were grouped as severe PH or control. Patients with severe PH included those with IPAH, pulmonary veno-occlusive disease, chronic thromboembolic pulmonary hypertension and sarcoidosis with severe PH. The control group consisted of other patients, who underwent lung transplantation for all other indications, including patients with lung fibrosis and various degrees of PH.
Patient records and outpatient visits were retrospectively reviewed. The follow-up was 100% complete and ended on 1 August 2016. The overall median follow-up was 34 [interquartile range (IQR), 20-50] and 41 (12-58) months for the severe PH patients, and 32 (18-48) months for control patients (P = 0.23).
At our institution, patients gave consent to allow us to handle their data for retrospective studies at the time of signing the informed consent for transplantation. Therefore, the institutional ethics committee waived the need for further patient consent for this study.
The variables postoperative extended ECMO support, secondary ECMO support, PGD and chronic lung allograft dysfunction were defined elsewhere [9] [10] [11] [12] [13] .
Extracorporeal membrane oxygenation in recipients with severe pulmonary hypertension
Clinical management of all lung transplanted patients as well as the ECMO protocol employed in patients with severe PH at our institution has been reported elsewhere [9] [10] [11] . Briefly, in patients who required preoperative ECMO support, the same ECMO system and cannulas were used for intraoperative support. In the remaining patients, ECMO was usually implanted directly before transplantation by percutaneous cannulation of the common femoral artery for the arterial inflow and percutaneous cannulation of the femoral vein for venous outflow. In children, who usually have small-diameter femoral arteries, the femoral artery and vein were surgically isolated and then cannulated. For antegrade leg perfusion, an additional 6F introducer sheath (Cordis Corp, Miami, FL, USA) was inserted into the femoral artery distal from the arterial cannula and connected to the arterial branch of the ECMO circuit. In all patients with severe PH, a catheter was intraoperatively placed in the left atrium (LA) to monitor LA pressure and gas exchanges for later ECMO weaning.
Postoperatively, the patients were transferred to the intensive care unit (ICU) under ECMO support, which was then extended for a minimum of 5 days. Early extubation was always attempted. For an early and safe extubation, ECMO flow was kept high (at least 4 l/min) and LA pressure was maintained at less than 10 mmHg, along with restrictive fluid management. After 5 days of ECMO treatment, the ECMO flow was gradually reduced. Continuous LA pressure measurement and echocardiography were used to ensure safe ECMO weaning and to decide whether left ventricle function had recovered. ECMO cannulas were removed without open surgery in patients who underwent ECMO implantation percutaneously [13] .
Echocardiography
Echocardiographic measurements of the left ventricular enddiastolic dimension, the proximal right ventricular outflow diameter, and of the left ventricular ejection fraction, as well as quantification of the tricuspid valve regurgitation were performed by a cardiologist, and calculated according to recommendations for cardiac chamber quantification by echocardiography in adults [14] . Two-dimensional echocardiography was used for measurement of linear diameters. An apical window could not be always obtained due to the presence of the left-sided anterolateral thoracotomy, especially early after transplantation. Therefore, the data were usually collected from a parasternal long axis and short axis view. In parasternal long axis crosschecked by short axis linear measurement, either M-Mode tracing or, in case of incorrect angle, 2D-guided linear measurement were used to obtain left ventricular end-diastolic and end-systolic internal diameter and to exclude regional wall motion abnormalities. Left ventricular ejection fraction was calculated using Teichholz formula.
The echocardiographic parameters were measured preoperatively and at 3 weeks, 3 months and 1 year after transplantation.
Statistics
Data collection and analysis were performed retrospectively using SPSS 24.0 (IBM, NY, USA). Primary endpoint was patient survival.
Categorical and continuous variables were summarized as percentages and median with IQR, respectively. The non-parametric Mann-Whitney test and the v 2 -test or the Fisher's exact tests were used for group comparisons of continuous and categorical variables, respectively.
The presence of any statistical difference between preoperative and at 1-year echocardiographic data in patients transplanted for severe PH was evaluated using the paired Student's t-test.
Survival estimates were calculated by the product-limit method of Kaplan-Meier. Differences of event free time between groups were quantified using the log-rank test.
P-values < _ 0.05 were considered statistically significant.
RESULTS
Preoperative and intraoperative patient characteristics
Between May 2010 and January 2016, 717 patients underwent lung transplantation at our institution. Thirty-eight (5%) patients underwent transplantation for severe PH. The remaining 679 (95%) patients were transplanted for other indications and formed the control group. During the study period, not a single case of heart-lung transplantation was performed for IPAH, pulmonary veno-occlusive disease, chronic thromboembolic pulmonary hypertension or sarcoidosis at our institution. Preoperative patient characteristics of each group are reported in Table 1 . Patients with severe PH showed a median pulmonary artery pressure of 68 mmHg (range 53-72 mmHg), and a reduced cardiac index of 2.1 l/min/m 2 (range 1.1-3.7 l/min/m 2 ), measured by right heart catheterization before transplantation.
Patients in the severe PH group showed a higher preoperative risk profile than patients in the control group (Table 1) .
Donor data and intraoperative results are reported in Table 2 . The majority of the severe PH patients (n = 36, 95%) were transplanted through a sternum sparing bilateral thoracotomy. The overall need for blood products and clotting factors was significantly higher in the severe PH than in the control group (Table 2) .
Postoperative course
The postoperative course was more complicated in the severe PH patients than the control group (Table 3 ). The patients with severe PH showed a significantly higher incidence of PGD grade 2 or 3 at 24, 48 and 72 h after transplantation, and a higher incidence of revision for bleeding and new haemodialysis treatment than control patients (Table 3 ). More patients with severe PH showed peripheral vascular complications after transplantation (P < 0.01). One severe PH patient developed a type B dissection 6 days after lung transplantation requiring thoracic endovascular aortic repair. Five (13%) patients with severe PH developed lower limb ischaemia after removal of the arterial cannula therefore requiring arterial embolectomy followed by leg fasciotomy in 2 cases. One patient developed a superficial secondary wound infection in the cannulation position of the ECMO.
Ventilation times as well as ICU and hospital stay times were longer in severe PH than control patients (Table 3) . However, in the severe PH group, the ventilation time (median 2 days, IQR 1-3 days) was shorter than the ECMO weaning time (median 7 days, IQR 6-9 days). Six (16%) patients showed a complicated postoperative course with prolonged ventilation and ICU stay times, as reported in Fig. 1 . Patient number 4 developed type B dissection, underwent thoracic endovascular aortic repair and required prolonged respiratory weaning. Patients 11, 18 and 24 underwent redo-thoracotomies for bleeding. The inadequate drainage of the paediatric venous cannula caused a prolonged ventilation time for Patient 13, who was 7 years old. Patient number 34 was bridged to transplant on veno-arterial ECMO and received a lobar transplantation. Postoperatively, she required a redo-tracheotomy for bleeding and showed several ICU readmissions requiring invasive ventilation. 
Survival and follow-up
Although the postoperative course was more complicated in severe PH than control patients, there was no significant difference between groups regarding in-hospital mortality (P = 0.97). One severe PH patient died 11 days after transplantation due to sudden cardiorespiratory failure, whose cause remained unclear; unfortunately, necropsy was not performed. Another severe PH patient died of pneumonia and sepsis 3 months after lung transplantation. Similarly, no significant differences were detected between groups regarding survival at 3 months, 1 year and 5 years after transplantation (P = 0.45, Table 3 and Fig. 2) .
At 1 year, patients with severe PH showed lower forced expiratory volume in 1 second values (% predicted) than control patients (Table 3) . However, forced expiratory volume in 1 second values (% predicted) at the last available spirometry showed no difference between groups (Table 3) .
Echocardiographic results
Transthoracic echocardiography was performed in all patients preoperatively. Three weeks after transplantation, echocardiographic data were available in 37 (97%) patients. Three months after transplantation, echocardiographic data were available in 33 (87%) patients, as 2 patients had died and the remaining 3 patients had not undergone an echocardiographic control. One year after transplantation, echocardiographic data were available in 25 (66%) patients, as 4 patients had died, 7 patients had not yet reached 1-year follow-up and 2 patients had not undergone the planned 1-year echocardiographic control.
Twenty-six (67%) patients showed pretransplant tricuspid regurgitation equal or more than grade 2. One year after transplant, none of the patients had more than mild tricuspid regurgitation (Fig. 3) . The echocardiographic data are reported in Table 4 and showed a significant increase of left ventricular enddiastolic dimension and LV ejection fraction as well as a significant decrease of the proximal right ventricular outflow diameter after 1 year.
DISCUSSION
This study, based on one of the largest case series of patients undergoing bilateral lung transplantation for severe PH, showed 3 important results.
First, although PH is considered to be a risk factor for mortality after lung transplantation [15] and, in our study, postoperative course was more complicated in patients with severe PH, survival did not differ between severe PH and control patients. Second, the increase of left ventricular end-diastolic dimension and decrease of the proximal right ventricular outflow diameter occurred as early as 3 weeks after lung transplantation (Table 4) , leading to improvement of the right ventricular contractility and improvement of the tricuspid valve function.
Third, this study confirmed the pivotal and versatile role of veno-arterial ECMO for transplanting patients with severe PH [11] . The postoperative support with veno-arterial ECMO allowed for early weaning from mechanical ventilation and recovery of the diastolic dysfunction of the left ventricle during the first days after transplantation. Thus, at our institution, since 2010, veno-arterial ECMO has replaced other forms of cardiopulmonary support in patients transplanted for severe PH, both preoperatively as bridge to transplantation, and intraoperatively instead of conventional cardiopulmonary bypass [9] . Peripheral implanted pumpless interventional lung assist (iLA) devices are not suitable for bridging patients with severe PH to transplantation, since a prerequisite for pumpless devices is the presence of a normal cardiac output. One option would be the central cannulation of the iLA device as a pulmonary artery-LA lung assist via sternotomy, as previously published by our group [16] . However, this approach required fully anaesthetic procedure with intubation and mechanical ventilation and therefore we abandoned it in favour of peripheral veno-arterial ECMO.
Other groups have recently reported on the use of perioperative veno-arterial ECMO support in severe PH patients undergoing lung transplantation [17] [18] [19] . For example, the Vienna group, in a series of 17 lung-transplanted patients for PH, showed a 6-month survival of 88%. In contrast to our experience, their general postoperative strategy consisted of prolonged mechanical ventilation with early ECMO weaning, lasting a median of 8 h after transplantation. However, they reported 4 patients with temporary left ventricular failure at the time of weaning from mechanical ventilation, suggesting that ECMO support may have been weaned too early in their study [18] . Moreover, previous studies described that weaning from mechanical ventilation in lung transplanted patients with severe PH as the underlying disease is commonly associated with elevated left ventricular preload, resulting in LV failure and cardiogenic pulmonary oedema and consequently prolonged sedation and mechanical ventilation [20] . Our previous data showed that the underlying mechanism for this syndrome may rather not be right, but rather left ventricle dysfunction due to the inability of the pretransplant small left ventricle to accommodate the increased preload after transplantation [11] . Others have since confirmed our findings [17] . In addition, the majority of patients with severe PH undergoing lung transplantation before 2010 without the actual ECMO protocol developed PGD grade 3 at 72 h. Therefore, we changed our strategy and used our ECMO protocol in all patients transplanted for severe PH.
The improvement of the left ventricular uptake and of the right ventricular dimensions leading to normal chamber diameters and ejection fraction at 1 year after transplantation supports the concept of performing lung transplantation under perioperative veno-arterial ECMO support instead of combined heart and lung transplantation in patients with severe PH [21, 22] . Indeed, the number of heart and lung transplantations has decreased in the past years, due to the shortage of available organs, the high complexity of the operation and postoperative course [15] . In our study, 67% of patients showed tricuspid valve regurgitation grade 2 or more. However, 1 year after lung transplantation, tricuspid valve regurgitation resolved in all patients. These data correlate with previously published studies. Birsan et al. [23] showed that normalization of the right ventricle wall thickness and end-diastolic dimension occurred within the first 12 postoperative months, with pre-existing tricuspid valve regurgitation completely resolving. Similarly, Crovetto et al. [24] showed an early reverse remodelling of the RV with a significant reduction of right heart diameters and improved indices of ventricular interdependency index in 21 patients 24 ± 14 days after lung transplantation.
Finally, our ECMO protocol allowed early weaning from the mechanical ventilation in the majority of patients, thus avoiding muscular deconditioning and reducing the potential risk of ventilator associated lung infections. It has been recently demonstrated that prolonged mechanical ventilation early after lung transplantation was associated with poorer overall survival [25] . On the contrary, the risks associated with a prolonged ECMO support, such the vascular complications, must be also weighed against the benefits of early ventilator weaning. However, careful patient monitoring with continuous control of O 2 leg saturation and surgical, instead of percutaneous, ECMO implantation in small patients may help avoiding these complications.
Limitations
Echocardiographic data were not available in some patients at 3 months and 1 year after transplantation. However, the majority of the missing data at 12 months were from patients who had not reached the 12-month time-point yet, before the end of follow-up.
In addition, different operators performed the echocardiography examinations and thus a certain degree of interobserver variability may be assumed.
The echocardiographic measurements used in this study may not assess cardiac remodelling properly. Actually, at our institution, since the beginning of 2016, all discharged patients transplanted for severe PH undergo 3D-echocardiographic study with evaluation of tricuspid valve annular kinetics and mitral valve annular kinetics for evaluation of LV diastolic function, through an apical window.
Some variables showed significant difference among groups. However, this inhomogeneity among groups was due to the inherent differences in the indication to transplantation, such as urgency for transplant, lung allocation scores pulmonary and pulmonary artery pressure values.
Finally, the control group did not consist of contemporary patients transplanted for severe PH without ECMO, because, since 2010, all these patients per protocol were transplanted with ECMO support [11] .
CONCLUSIONS
In patients transplanted for severe PH, the postoperative venoarterial ECMO support favours the recovery of normal cardiac function, which is initiated by the lung transplantation itself. Our ECMObased protocol allowed early weaning from mechanical ventilation in most patients. Despite a more complicated postoperative course, early and mid-term survival was similar between patients with severe PH and patients transplanted for other indications.
